HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial of Savolitinib plus TAGRISSO® at the 2022 WCLC Annual Meeting

— 49% ORR amongst SAVANNAH patients with higher MET levels —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 12, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the first presentation of results from the ongoing SAVANNAH global Phase II trial at the upcoming...

Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors --Toripalimab continues to demonstrate synergy as the cornerstone in innovative combination therapies SHANGHAI, China, June 07, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877;...

ZeroFox Expands Canadian Presence, Delivering Over 60% Year-Over-Year Increase in Impersonation and Malicious Content Takedowns for Canadian Customers

Expansion includes new partnerships to deliver external cybersecurity solutions to Canadian enterprisesWASHINGTON, April 27, 2022 (GLOBE NEWSWIRE via SEAPRWire.com) -- ZeroFox, a leading external cybersecurity provider, today announces new disruption research and expanded partnerships to serve Canadian enterprises. A new partnership with Quick Intelligence will extend critical threat intelligence, digital...

Hua Medicine Announces 2021 Annual Results

SHANGHAI, CHINA, Mar 17, 2022 - (ACN Newswire via SEAPRWire.com) - Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process...

Eisai: Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiwan for the First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

TOKYO, Jan 31, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s KEYTRUDA (generic name: pembrolizumab) has been approved in Taiwan for...

The CREB-binding protein (CBP)/beta-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)

TOKYO, Nov 1, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) / beta-catenin inhibitor E7386, a medium-molecular weight compound created through collaboration research between Eisai and PRISM, has achieved the clinical POC (Proof of Concept).Eisai is...

Hua Medicine Announces 2020 Interim Results

SHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire via SEAPRWire.com) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). During the Reporting Period, the New Drug Application (NDA) of...

FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC)

TOKYO and KENILWORTH, N.J., Aug 12, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of LENVIMA, the orally available...

Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab

TOKYO, Mar 30, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate (product name: LENVIMA / Kisplyx, "lenvatinib"), in...

APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA

FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, Mar 4, 2021 - (ACN Newswire via SEAPRWire.com) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial...